NCT07000955

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg Administered Multiple Times in Chinese Patients With Moderate to Severe Obesity

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 98 (actual)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Tirzepatide	Tirzepatide administered subcutaneously (SC) once a week.
DRUG	Placebo	Placebo administered subcutaneously (SC) once a week.
DRUG	IBI362	IBI362 administered subcutaneously (SC) once a week.

Timeline

• Start date: 2025-06-17
• Primary completion: 2026-09-30
• Completion: 2027-05-14
• First posted: 2025-06-03
• Last updated: 2025-12-15

Locations

1 site across 1 country: China